Dangane da sakamakon bin shekaru 5 na mahimman PACE fitina da aka buga a cikin Journal of Hematology, panatinib (Ponatinib, Iclusig) ya ci gaba da dawwama a cikin majiyyatan da ke fama da cutar sankarar myeloid na yau da kullum (CP-CML) dauki.
A matsakaita bin watanni 56.8, 60% (n = 159) na 267 marasa lafiya marasa lafiya sun sami babbar amsa ta salula (MCyR). 54% (n = 144) na marasa lafiya suna da cikakkiyar amsawar salula. 40% (n = 108) patients achieved a major molecular response (MMR), and 24% (n = 64) achieved a molecular response. During the median follow-up period, at 12 months, 82% of patients achieved MCyR, and at 5 years, an estimated 59% of patients achieved MMR. The most common (≥40%) adverse events (TEAE) were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%) and constipation (41%).
In the entire 270 patient cohort, more than 90% of patients had received at least 2 TKI treatments. Investigators found that the response was related to long-term results. The 5-year progression-free survival (PFS) is expected to be 53%, and the overall survival (OS) is 73%.
Sakin waɗannan bayanan muhimmin abu ne saboda ya nuna cewa Ponatinib har yanzu zaɓi ne na magani mai tasiri ga marasa lafiya da suka dace da gazawar TKI da ta gabata (gami da marasa lafiya da maye gurbi na T315I).
